Zydus Cadila has received final approval from the USFDA to market Doxycycline Hyclate capsules USP, antibiotic used for treating bacterial infections.
“Zydus Cadila has received final approval from the USFDA to market Doxycycline Hyclate Capsules USP, 50 mg and 100 mg,” the company has said in a regulatory filing.
It is a tetracycline antibiotic used for the treatment of a wide variety of bacterial infections, including those that cause acne. “This medication is also used for prophylaxis of malaria,” the filing said.
The capsules will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad. The group has more than 195 approvals so far.
Zydus Cadila is a global pharmaceutical company that develops, manufactures and markets a broad range of healthcare therapies. The group employs over 21,000 people worldwide.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.